Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study
September 29th 2019
Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.